Riskpilot← Back to searchSign inGet full accessCercare Medical A/S
A/SActiveCVR 35483489Inge Lehmanns Gade 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 201329 employees
Revenue 2024
DKK -31,6M
+30% vs 2023
EBITDA margin
172.7%
-28% vs 2023
Equity ratio
84.2%
Financial strength
Net profit 2024
DKK -53,3M
-26% vs 2023
| Revenue | DKK -31,6M | +30% |
| EBITDA | DKK -54,7M | -28% |
| Net profit | DKK -53,3M | -26% |
| Total assets | DKK 36,6M | +38% |
| Equity | DKK 30,8M | +55% |
| Employees | 29 | — |
Legal name
Cercare Medical A/S
CVR number
35483489
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. september 2013
Share capital
DKK 1.307.253
Employees
29 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af tre medlemmer af bestyrelsen i forening eller af Selskabets administrerende direktør og bestyrelsesformanden i forening.
Company purpose
Selskabets formål er at drive en virksomhed til udvikling, handel og salg af computer baseret beslutningsstøtteværktøj til brug i kliniske omgivelser og til at estimere omfanget af salvageable væv hos patienter med akut iskæmisk slagtilfælde, og andre beslægtede aktiviteter.
Address
Inge Lehmanns Gade 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -2.852 | 3.045 | -18.800 | -24.371 | -31.642 |
| Staff expenses | -11.220 | -14.678 | -14.938 | -18.376 | -23.015 |
| EBITDA | -16.039 | -11.633 | -33.862 | -42.747 | -54.657 |
| Depreciation & amort. | -560 | -671 | -666 | -633 | -222 |
| EBIT | -16.599 | -12.304 | -34.528 | -43.380 | -54.879 |
| Net financials | -153 | -218 | -415 | -1.788 | -1.241 |
| Profit before tax | -16.752 | -12.522 | -34.943 | -45.168 | -56.120 |
| Tax | -2.097 | -1.664 | -3.016 | -2.743 | -2.835 |
| Net profit | -14.654 | -10.858 | -31.927 | -42.425 | -53.285 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 43.273 | 37.770 | 9.359 | 26.541 | 36.600 |
| Equity | 40.808 | 35.537 | -3.825 | 19.855 | 30.829 |
| Long-term debt | 767 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.699 | 2.233 | 13.184 | 6.686 | 5.772 |
| Total debt | 2.466 | 2.233 | 13.184 | 6.686 | 5.772 |
EBITDA margin
-5465705300.0%
This company
15.8%
Market median
-34593071619% vs market
20202024
Equity ratio
84.2%
This company
38.2%
Market median
+120% vs market
20202024
Return on equity
-172.8%
This company
18.4%
Market median
-1039% vs market
20202024
Net profit margin
-5328536500.0%
This company
8.1%
Market median
-65784401335% vs market
20202024
Asset turnover
-0.86×
This company
1.12×
Market median
-177% vs market
20202024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KB Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2026 | |
| Board of Directors | 2023 | |
| Chairman | 2021 | |
| Board of Directors | 2013 | |
| Board of Directors | 2016 | |
| Former (4) | ||
| Chairman | 2013 – 2016 | |
| Board of Directors | 2022 – 2023 | |
| Chairman | 2017 – 2021 | |
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2025 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Individual | 5–9.99% | 5–9.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2018 | |
| Individual | 5–9.99% | 5–9.99% | 2023 | |
| Company | 10–14.99% | 10–14.99% | 2016 | |
| Company | 20–24.99% | 20–24.99% | 2014 | |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2020 | |
| Company | 5–9.99% | 5–9.99% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cercare Medical A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kim Beuschau Mouridsen | Chief Executive Officer | 0 companies |
| Ulla Bagger-Sørensen | Board of Directors | 0 companies |
| Jon Ingi Benediktsson | Chairman | 0 companies |
| Konstantinos Dimitrakopoulos | Board of Directors | 0 companies |
| Belinda Jane Oakland | Board of Directors | 0 companies |
| Jonathan Andrew Lerner | Board of Directors | 0 companies |
| Jeppe Øvli Øvlesen | Chairman | 0 companies |
| Odd Torland | Chairman | 0 companies |
| Aitana Peire Morais | Board of Directors | 0 companies |
| Mikkel Bo Hansen | Board of Directors | 0 companies |
| Marit Salte | Board of Directors | 0 companies |